Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $79.00

by · The Cerbat Gem

Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its target price increased by JPMorgan Chase & Co. from $78.00 to $79.00 in a research note published on Tuesday morning,Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

Several other analysts have also weighed in on HALO. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. TD Cowen increased their target price on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Wells Fargo & Company raised their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Finally, Zacks Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average target price of $99.64.

View Our Latest Research Report on Halozyme Therapeutics

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $122.96 on Tuesday. The company has a 50 day moving average of $115.26 and a 200-day moving average of $84.57. Halozyme Therapeutics has a 1-year low of $61.22 and a 1-year high of $134.00. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The company has a market cap of $13.96 billion, a PE ratio of 26.44, a price-to-earnings-growth ratio of 0.49 and a beta of 0.92.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $492.97 million for the quarter, compared to analyst estimates of $491.63 million. During the same quarter last year, the business posted $1.72 EPS. The firm’s revenue for the quarter was up 39.1% on a year-over-year basis. As a group, equities research analysts forecast that Halozyme Therapeutics will post 8.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $82,482,605.40. The trade was a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock valued at $13,538,046 in the last 90 days. Corporate insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently added to or reduced their stakes in HALO. Bank of America Corp DE purchased a new stake in Halozyme Therapeutics in the 2nd quarter valued at $214,504,000. William Blair Investment Management LLC purchased a new position in Halozyme Therapeutics during the 2nd quarter worth $196,540,000. Congress Asset Management Co. grew its stake in shares of Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after acquiring an additional 1,052,509 shares in the last quarter. Royal London Asset Management Ltd. grew its stake in shares of Halozyme Therapeutics by 12.4% in the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock worth $141,732,000 after acquiring an additional 200,262 shares in the last quarter. Finally, First Trust Advisors LP raised its holdings in shares of Halozyme Therapeutics by 46.5% in the first quarter. First Trust Advisors LP now owns 1,482,340 shares of the biopharmaceutical company’s stock valued at $95,804,000 after purchasing an additional 470,558 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

  • Positive Sentiment: Third-quarter revenue rose 39% year over year to a record $493 million, while royalty revenue climbed 44% to $341 million. Adjusted EPS of $2.39 also exceeded analysts’ estimates of about $2.30. Halozyme Q3 2026 results and guidance
  • Positive Sentiment: The company raised its full-year 2026 outlook, projecting revenue of $1.86 billion–$1.925 billion, royalty revenue of $1.235 billion–$1.255 billion, and adjusted EPS of $8.75–$9.05. It also reported expanded ENHANZE collaborations with three existing partners and three programs entering Phase 1 development. Halozyme Q3 2026 results and guidance
  • Negative Sentiment: HALO shares fell despite the earnings beat and higher guidance. The market reaction suggests investors may have been looking for stronger results or may have taken profits, though the cited reports do not identify a specific cause. Halozyme surprises with Q3 sales but stock drops

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.

Further Reading